These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31671330)

  • 1. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
    Fan YY; Ding W; Zhang C; Fu L; Xu DX; Chen X
    Int Immunopharmacol; 2019 Dec; 77():105911. PubMed ID: 31671330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
    Zhang DG; Zhang C; Wang JX; Wang BW; Wang H; Zhang ZH; Chen YH; Lu Y; Tao L; Wang JQ; Chen X; Xu DX
    Toxicol Appl Pharmacol; 2017 Jan; 314():39-47. PubMed ID: 27865854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
    Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
    Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand.
    Carino A; Biagioli M; Marchianò S; Scarpelli P; Zampella A; Limongelli V; Fiorucci S
    Pharmacol Res; 2018 May; 131():17-31. PubMed ID: 29530598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
    Xu W; Lu C; Zhang F; Shao J; Yao S; Zheng S
    FEBS J; 2017 Jan; 284(1):114-133. PubMed ID: 27896916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
    Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
    Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatoprotection of yangonin against hepatic fibrosis in mice via farnesoid X receptor activation.
    Wang X; Fu T; Wang J; Wang C; Liu K; Wu J; Sun H; Ma X; Sun P; Meng Q
    Int Immunopharmacol; 2019 Oct; 75():105833. PubMed ID: 31450152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
    Zhou J; Cui S; He Q; Guo Y; Pan X; Zhang P; Huang N; Ge C; Wang G; Gonzalez FJ; Wang H; Hao H
    Nat Commun; 2020 Jan; 11(1):240. PubMed ID: 31932588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obeticholic acid differentially regulates hepatic injury and inflammation at different stages of D-galactosamine/lipopolysaccharide-evoked acute liver failure.
    Ding W; Fan YY; Zhang C; Fu L; Chen X; Xu DX
    Eur J Pharmacol; 2019 May; 850():150-157. PubMed ID: 30772394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice.
    Li J; Liu C; Zhou Z; Dou B; Huang J; Huang L; Zheng P; Fan S; Huang C
    Phytother Res; 2021 Jun; 35(6):3351-3364. PubMed ID: 33784797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury.
    Zhu JB; Xu S; Li J; Song J; Luo B; Song YP; Zhang ZH; Chen YH; Xie DD; Yu DX; Xu DX
    Eur J Pharmacol; 2018 Nov; 838():60-68. PubMed ID: 30196109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
    Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
    Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
    J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
    Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
    Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
    Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
    PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
    Vignozzi L; Morelli A; Cellai I; Filippi S; Comeglio P; Sarchielli E; Maneschi E; Vannelli GB; Adorini L; Maggi M
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):277-292. PubMed ID: 27425465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice.
    Wu H; Liu G; He Y; Da J; Xie B
    Eur J Pharmacol; 2019 Sep; 858():172393. PubMed ID: 31085240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ampelopsin attenuates carbon tetrachloride-induced mouse liver fibrosis and hepatic stellate cell activation associated with the SIRT1/TGF-β1/Smad3 and autophagy pathway.
    Ma JQ; Sun YZ; Ming QL; Tian ZK; Yang HX; Liu CM
    Int Immunopharmacol; 2019 Dec; 77():105984. PubMed ID: 31677501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis.
    Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corcetto F; Corno C; Maneschi E; Pini A; Adorini L; Vannelli GB; Maggi M; Vignozzi L
    J Steroid Biochem Mol Biol; 2017 Apr; 168():26-37. PubMed ID: 28115235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.